varenicline

Reactions 1451 - 11 May 2013 S Varenicline Neuropsychiatric events: 4 case reports Three men and four women with psychiatric comorbidities developed neuropsychiatric adverse events during treatment with varenicline for smoking cessation [routes and dosages not stated]. A 58-year-old man with PTSD developed worsening mood and suicidal ideation within 30 days of starting varenicline therapy. Varenicline was stopped and his suicidal thoughts resolved. A 39-year-old man with depression and PTSD began experiencing worsening mood with a passive death wish about 35 days after varenicline initiation. He began receiving citalopram, which was tapered off after varenicline was later withdrawn because his mood improved. A 42-year-old woman with bipolar disorder developed emotional lability, depression and hallucinations from about 7 days after starting varenicline. Twenty days after withdrawal of the drug, most of her symptoms had resolved. A 49-year-old man with depression was hospitalised for depression and suicidal ideation after a rechallenge of self- initiated varenicline. The man had initially taken it for 2 weeks before self-discontinuing due to low mood. After 5 weeks he restarted the drug, taking it for 3 weeks; he stopped a week before the current admission. He began receiving fluoxetine and nicotine replacement, and received one session of electroconvulsive therapy. He was discharged after a 3-day admission, and required no further treatment for depression since discharge, despite becoming non-compliant with fluoxetine. Author comment: "[W]e report four cases of varenicline- associated neuropsychiatric adverse effects". Cantrell M, et al. Adverse neuropsychiatric events associated with varenicline use in veterans: a case series. Issues in Mental Health Nursing 33: 665-9, No. 10, Oct 2012 - USA 803086436 1 Reactions 11 May 2013 No. 1451 0114-9954/10/1451-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Upload: md-ibrahim-h

Post on 23-Dec-2016

213 views

Category:

Documents

1 download

Report

Download

Embed Size (px):

TRANSCRIPT

Reactions 1451 - 11 May 2013

SVarenicline

Neuropsychiatric events: 4 case reportsThree men and four women with psychiatric comorbidities

developed neuropsychiatric adverse events during treatmentwith varenicline for smoking cessation [routes and dosages notstated].

A 58-year-old man with PTSD developed worsening moodand suicidal ideation within 30 days of starting vareniclinetherapy. Varenicline was stopped and his suicidal thoughtsresolved.

A 39-year-old man with depression and PTSD beganexperiencing worsening mood with a passive death wish about35 days after varenicline initiation. He began receivingcitalopram, which was tapered off after varenicline was laterwithdrawn because his mood improved.

A 42-year-old woman with bipolar disorder developedemotional lability, depression and hallucinations from about7 days after starting varenicline. Twenty days after withdrawalof the drug, most of her symptoms had resolved.

A 49-year-old man with depression was hospitalised fordepression and suicidal ideation after a rechallenge of self-initiated varenicline. The man had initially taken it for 2 weeksbefore self-discontinuing due to low mood. After 5 weeks herestarted the drug, taking it for 3 weeks; he stopped a weekbefore the current admission. He began receiving fluoxetineand nicotine replacement, and received one session ofelectroconvulsive therapy. He was discharged after a 3-dayadmission, and required no further treatment for depressionsince discharge, despite becoming non-compliant withfluoxetine.

Author comment: "[W]e report four cases of varenicline-associated neuropsychiatric adverse effects".Cantrell M, et al. Adverse neuropsychiatric events associated with varenicline usein veterans: a case series. Issues in Mental Health Nursing 33: 665-9, No. 10, Oct2012 - USA 803086436

Nicotinic Partial Agonists Varenicline and Sazetidine-A ... Papers/665full.pdf · nicotine and the 4 2 nicotinic partial agonists varenicline and sazetidine-A in mouse models of anxiety

Chapter 3 Synthesis of Varenicline - INFLIBNETshodhganga.inflibnet.ac.in/bitstream/10603/2183/8/08_chapter 3.pdf · and second messengers. Varenicline is partial agonist alone and

Champix, INN Varenicline tartrate · manufacturing site for the FP - Primary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing

Patient Group Direction for the Supply of Varenicline ......Tayside PGD - Title Supply of Varenicline (Champix ®) by Authorised Community Pharmacists Date Effective: July 2016 Review

Patient Group Direction for the supply of varenicline ... · PDF file(Champix ®) by authorised community pharmacists working in ... Black Triangle Dose(s) Days 1 - 3: ... by authorised

NIAAA Spectrum, Volume 5, Issue 2, June 2013 · varenicline reduced alcohol drinking, craving, and the pleasant effects of alcohol and that varenicline treatment led to a greater

[Product Monograph Template - Standard]€¦ · January 22, 2019 Submission Control No: 221214. CHAMPIX (varenicline tartrate) -Product Monograph Page 2of 60 ... Stevens-Johnson syndrome

New Pharmacological Agents to Aid Smoking … et al 2016...Bupropion, nicotine replacement therapy (NRT), and varenicline are licensed as first-line smoking cessation aids in Australia,

Evaluating neuropsychiatric risks with varenicline in ... · PDF file1 Evaluating neuropsychiatric risks with varenicline in patients with psychiatric disorders Shermaine Ngo, LMPS

Double-blind, Randomized, Multi- Center Placebo-Controlled Trial of Varenicline in the Treatment of SCA-3 (Achantia) Theresa A. Zesiewicz, MD FAAN Professor

HOW DOES CHAMPIX (VARENICLINE TARTRATE) WORK? › ... › files › pp-chm-irl-0154_high_res_moa_do… · Changes in behaviour or thinking, anxiety, psychosis, mood swings, aggressive

data Sheet - Medsafe.govt.nz · DATA SHEET . 1. PRODUCT NAME . CHAMPIX ® (varenicline, as tartrate) 0.5 mg and 1 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION